Identification and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeficiency Virus Protease Inhibitors and Impair Viral Replication
- 1 February 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (2) , 732-735
- https://doi.org/10.1128/aac.00690-06
Abstract
Two novel human immunodeficiency virus protease mutations, I84C and I84A, were identified in patient isolates. The mutants with I84C displayed high-level resistance (median, at least 56-fold) to nelfinavir and saquinavir, but the majority remained susceptible to lopinavir. In contrast, isolates with the I84A mutation exhibited ≥33-fold median increased levels of resistance to nelfinavir, indinavir, amprenavir, ritonavir, lopinavir, saquinavir, and atazanavir. Isolates with the I84A or I84C mutation tended to be more resistant than the isolates with the I84V mutation. Modeling of the structure of the mutant proteases indicated that the I84V, I84C, and I84A mutations all create unoccupied volume in the active site, with I84A introducing the greatest change in the accessible surface area from that of the wild-type structure.Keywords
This publication has 16 references indexed in Scilit:
- Kinetic, Stability, and Structural Changes in High-resolution Crystal Structures of HIV-1 Protease with Drug-resistant Mutations L24I, I50V, and G73SJournal of Molecular Biology, 2005
- Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavirAntiviral Research, 2005
- Amprenavir or Fosamprenavir plus Ritonavir in HIV InfectionDrugs, 2005
- Comparing the Accumulation of Active- and Nonactive-Site Mutations in the HIV-1 ProteaseBiochemistry, 2004
- Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsJournal of Medical Virology, 2004
- Identification of I50L as the Signature Atazanavir (ATV)–Resistance Mutation in Treatment‐Naive HIV‐1–Infected Patients Receiving ATV‐Containing RegimensThe Journal of Infectious Diseases, 2004
- Secondary Mutations M36I and A71V in the Human Immunodeficiency Virus Type 1 Protease Can Provide an Advantage for the Emergence of the Primary Mutation D30NBiochemistry, 2003
- Relationship between In Vitro Human Immunodeficiency Virus Type 1 Replication Rate and Virus Load in PlasmaJournal of Virology, 2003
- The Protein Data BankNucleic Acids Research, 2000
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995